Literature DB >> 21127735

Ubiquitination-dependent regulation of signaling receptors in cancer.

Wei-Chun Huangfu1, Serge Y Fuchs.   

Abstract

Ubiquitination of signaling cell surface receptors is a key mechanism regulating the availability of these receptors to interact with extracellular ligands. Accordingly, this regulation determines the sensitivity of cells to the humoral and locally secreted regulators of cell function, proliferation, and viability. Alterations in receptor ubiquitination and degradation are often encountered in cancers. Malignant cells utilize modified ubiquitination of signaling receptors to augment or attenuate signaling pathways on the basis of whether the outcome of this signaling is conducive or not for tumor growth and survival. These mechanisms as well as their significance for the treatment of human cancers are discussed.

Entities:  

Keywords:  E3 ligase; cancer; kinase; receptor; signal transduction; ubiquitin

Year:  2010        PMID: 21127735      PMCID: PMC2994580          DOI: 10.1177/1947601910382901

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  121 in total

Review 1.  Vesicular trafficking and autophagosome formation.

Authors:  A Longatti; S A Tooze
Journal:  Cell Death Differ       Date:  2009-04-17       Impact factor: 15.828

Review 2.  The role of interferons in the treatment of osteosarcoma.

Authors:  Jeremy Whelan; Daniel Patterson; Martha Perisoglou; Stefan Bielack; Neyssa Marina; Sigbjorn Smeland; Mark Bernstein
Journal:  Pediatr Blood Cancer       Date:  2010-03       Impact factor: 3.167

3.  RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation.

Authors:  C B Thien; F Walker; W Y Langdon
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

4.  Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2.

Authors:  L N Klapper; H Waterman; M Sela; Y Yarden
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

Review 5.  The role of prolactin in mammary carcinoma.

Authors:  Charles V Clevenger; Priscilla A Furth; Susan E Hankinson; Linda A Schuler
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

Review 6.  RNF11 is a multifunctional modulator of growth factor receptor signalling and transcriptional regulation.

Authors:  Peter Azmi; Arun Seth
Journal:  Eur J Cancer       Date:  2005-10-13       Impact factor: 9.162

7.  Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells.

Authors:  K G Suresh Kumar; Jianghuai Liu; Ying Li; Duonan Yu; Andrei Thomas-Tikhonenko; Meenhard Herlyn; Serge Y Fuchs
Journal:  Cancer Biol Ther       Date:  2007-06-13       Impact factor: 4.742

Review 8.  Pael receptor, endoplasmic reticulum stress, and Parkinson's disease.

Authors:  Ryosuke Takahashi; Yuzuru Imai
Journal:  J Neurol       Date:  2003-10       Impact factor: 4.849

9.  Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking.

Authors:  Inger Helene Madshus; Espen Stang
Journal:  J Cell Sci       Date:  2009-10-01       Impact factor: 5.285

10.  Induction of homologue of Slimb ubiquitin ligase receptor by mitogen signaling.

Authors:  Vladimir S Spiegelman; Weigang Tang; Andrew M Chan; Makoto Igarashi; Stuart A Aaronson; David A Sassoon; Masaru Katoh; Thomas J Slaga; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2002-07-31       Impact factor: 5.157

View more
  27 in total

1.  Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis.

Authors:  Hui Zheng; Juan Qian; Christopher J Carbone; N Adrian Leu; Darren P Baker; Serge Y Fuchs
Journal:  Blood       Date:  2011-08-10       Impact factor: 22.113

Review 2.  Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.

Authors:  Christopher J Carbone; Serge Y Fuchs
Journal:  J Cell Biochem       Date:  2014-01       Impact factor: 4.429

Review 3.  Otubain 1: a non-canonical deubiquitinase with an emerging role in cancer.

Authors:  Matthew Saldana; Kacey VanderVorst; Anastasia L Berg; Hyun Lee; Kermit L Carraway
Journal:  Endocr Relat Cancer       Date:  2019-01-01       Impact factor: 5.678

4.  Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia.

Authors:  Bin Zhao; Sabyasachi Bhattacharya; Qiujing Yu; Serge Y Fuchs
Journal:  Leuk Lymphoma       Date:  2017-05-15

5.  E3 Ubiquitin Ligase RNF125 Activates Interleukin-36 Receptor Signaling and Contributes to Its Turnover.

Authors:  Siddhartha S Saha; Gary Caviness; Guanghui Yi; Ernest L Raymond; M Lamine Mbow; C Cheng Kao
Journal:  J Innate Immun       Date:  2017-11-25       Impact factor: 7.349

Review 6.  Ubiquitination-mediated regulation of interferon responses.

Authors:  Serge Y Fuchs
Journal:  Growth Factors       Date:  2012-03-07       Impact factor: 2.511

7.  Tyrosine phosphorylation of protein kinase D2 mediates ligand-inducible elimination of the Type 1 interferon receptor.

Authors:  Hui Zheng; Juan Qian; Darren P Baker; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2011-08-24       Impact factor: 5.157

8.  Ligand-stimulated downregulation of the alpha interferon receptor: role of protein kinase D2.

Authors:  Hui Zheng; Juan Qian; Bentley Varghese; Darren P Baker; Serge Fuchs
Journal:  Mol Cell Biol       Date:  2010-12-20       Impact factor: 4.272

9.  A BRISC-SHMT complex deubiquitinates IFNAR1 and regulates interferon responses.

Authors:  Hui Zheng; Vibhor Gupta; Jeffrey Patterson-Fortin; Sabyasachi Bhattacharya; Kanstantsin Katlinski; Junmin Wu; Bentley Varghese; Christopher J Carbone; Bernadette Aressy; Serge Y Fuchs; Roger A Greenberg
Journal:  Cell Rep       Date:  2013-09-26       Impact factor: 9.423

10.  Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses.

Authors:  S Bhattacharya; W-C HuangFu; G Dong; J Qian; D P Baker; J Karar; C Koumenis; J A Diehl; S Y Fuchs
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.